NEW YORK (GenomeWeb News) - Aviva Systems Biology will produce antibodies that the Institute for Systems Biology will use to identify liver toxicity biomarkers, Aviva said Wednesday.
Under the terms of the collaborative agreement, Aviva will develop and produce the antibodies from a list of proteins provided by the ISB.
ISB will then assess the efficacy of these antibodies and will use them to find biomarker proteins that work as early liver toxicity biomarkers.
Aviva said the antibodies will be used in surface plasmon resonance imaging, a method of detecting proteins at density levels lower than is currently possible with mass spectrometry and other technologies.
Aviva said it has an inventory of more than 12,000 target peptide-specific antibodies that represent over 4,000 human and mouse targets.